[{"id":"d2f28e68-db4b-42b9-85cb-b34ffca07748","acronym":"","url":"https://clinicaltrials.gov/study/NCT03125642","created_at":"2021-01-18T15:23:59.295Z","updated_at":"2024-07-02T16:35:30.655Z","phase":"Phase 2","brief_title":"Auto Stem Cell Transplant for Lymphoma Patients","source_id_and_acronym":"NCT03125642","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" ALK • CD4 • TCL1A","pipe":" | ","alterations":" ALK positive","tags":["ALK • CD4 • TCL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Depocyte (liposomal cytarabine) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/20/2017","start_date":" 04/20/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-11-02"},{"id":"71f85a29-45a0-417c-9df1-5ef02c25e12e","acronym":"PTCL-CHEPA","url":"https://clinicaltrials.gov/study/NCT05006664","created_at":"2021-08-16T16:54:36.262Z","updated_at":"2024-07-02T16:36:25.042Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin in Combination With CHEP in Patient With PTCL","source_id_and_acronym":"NCT05006664 - PTCL-CHEPA","lead_sponsor":"Czech Lymphoma Study Group","biomarkers":" ALK • TNFRSF8 • TCL1A","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["ALK • TNFRSF8 • TCL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2021-09-01"},{"id":"3d931a31-b046-492c-8fd8-af76f3577629","acronym":"PROPEL","url":"https://clinicaltrials.gov/study/NCT00364923","created_at":"2021-01-18T01:15:54.958Z","updated_at":"2024-07-02T16:36:52.212Z","phase":"Phase 2","brief_title":"Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT00364923 - PROPEL","lead_sponsor":"Acrotech Biopharma LLC","biomarkers":" TCL1A","pipe":"","alterations":" ","tags":["TCL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Folotyn (pralatrexate)"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 01/01/2009","primary_completion_date":" 01/01/2009","study_txt":" Completion: 02/24/2009","study_completion_date":" 02/24/2009","last_update_posted":"2019-12-19"},{"id":"d213f303-4daa-4ffe-886c-f96b8e4d3c0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03356678","created_at":"2021-01-18T16:34:12.273Z","updated_at":"2024-07-02T16:37:15.966Z","phase":"","brief_title":"Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03356678","lead_sponsor":"Samsung Medical Center","biomarkers":" ALK • TNFRSF8 • TCL1A","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • TNFRSF8 • TCL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Folotyn (pralatrexate)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 09/23/2016","start_date":" 09/23/2016","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 06/30/2017","study_completion_date":" 06/30/2017","last_update_posted":"2017-11-29"}]